Efficacy and safety of chemoradiation with cisplatin plus capecitabine in localized squamous cell carcinoma of the anal canal

Background Localized Squamous Cell Anal Cancer (SCCAC) is a rare disease. The standard of care treatment with curative intent is chemoradiation (CRT) with mitomycin (MMC) or cisplatin (CDDP) plus infusional 5-Fluoracil (5-FU). Capecitabine may replace 5-FU in MMC doublet. However, MMC and infusional pumps are frequently unavailable in underdeveloped countries. CCDP and capecitabine are widely available, but there is no prospective data about the feasibility and efficacy of this combination in a definitive SCCAC CRT setting. Methods A Prospective cohort study aimed to evaluate the safety and efficacy of treatment with chemoradiation with CDDP 60mg/m2 D1 and D29 plus Capecitabine 825mg/m2 BID in a population without MMC and infusional pump access. Eligible patients (pts) had T2-4, N0-3, and M0 disease candidates for a full curative CRT regimen. The study data were prospectively collected using REDCap. The primary endpoint was the response by RECIST v.1.1 at 24 weeks(w). The secondary endpoints included toxicity by CTCAE v.5.0, PFS, and OS. Results We enrolled 40 consecutive pts between Aug/2019-Dec/2022 in a tertiary cancer center in Brazil. The median age was 61.6y, the majority were stage III (n = 31, 77.5%) and ECOG 1 (n = 20, 50%). HIV + serology was observed in 11 pts (27,5%). All patients received CRT, with a median dose of 54Gy in the primary tumor and 45Gy in the elective nodes. At 8w, 35% (n = 14) had a complete response (CR), 50% (n = 20) partial response (PR), and 2.5% (n = 1) progressive disease (PD). Considering the 35 participants evaluable for response at 24 weeks months by RECIST v.1.1, the disease control rate was 88.5% (n = 31). CR was observed in 47,5% (n = 19), PR in 20% (n = 8), and PD in 12,5% (n = 5). 11 pts had disease recurrence, and six died. The 1y estimated OS was 94.7% (IC95%: 80.7–98.6%), and 1y estimated PFS was 75.3% (IC95%:57.8–86.3%). Colostomy-free survival at one year was 89.6% (IC95%: 74.7–95.9%). Regarding toxicities, any grade 3/4 toxicity was present in 45% (n = 18) being the main G3/4 clinical toxicity radiodermatitis. Conclusions The CRT regimen with C + CDDP represents an alternative treatment for localized anal canal tumors in a population that does not have access to MMC and 5-FU infusion pumps. Further studies in this population are encouraged to confirm these findings.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-20
DOI
https://doi.org/10.1186/s12885-026-17229-y
Primary Topic
Colorectal and Anal Carcinomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of chemoradiation with cisplatin plus capecitabine in localized squamous cell carcinoma of the anal canal

Carolina Ribeiro Victor, Abraão Dornellas, Karim Yaqub Ibrahim, Caio Sérgio Rizkallah Nahas et al.
BMC Cancer
Colorectal and Anal Carcinomas
article

Efficacy and safety of chemoradiation with cisplatin plus capecitabine in localized squamous cell carcinoma of the anal canal

Carolina Ribeiro Victor, Abraão Dornellas, Karim Yaqub Ibrahim, Caio Sérgio Rizkallah Nahas, Luciana Bastos Valente Alban, Denis Artico Galhera, Paulo M. Hoff, Maria Ignez Braghiroli, Carlos Frederico Sparapan Marques, Camila Motta Venchiarutti Moniz, Cinthia D. Ortega, Carolina Teixeira Muratori, Andrè Chen, Renata Rodrigues da Cunha Colombo Bonadio
article en

Abstract

Background Localized Squamous Cell Anal Cancer (SCCAC) is a rare disease. The standard of care treatment with curative intent is chemoradiation (CRT) with mitomycin (MMC) or cisplatin (CDDP) plus infusional 5-Fluoracil (5-FU). Capecitabine may replace 5-FU in MMC doublet. However, MMC and infusional pumps are frequently unavailable in underdeveloped countries. CCDP and capecitabine are widely available, but there is no prospective data about the feasibility and efficacy of this combination in a definitive SCCAC CRT setting. Methods A Prospective cohort study aimed to evaluate the safety and efficacy of treatment with chemoradiation with CDDP 60mg/m2 D1 and D29 plus Capecitabine 825mg/m2 BID in a population without MMC and infusional pump access. Eligible patients (pts) had T2-4, N0-3, and M0 disease candidates for a full curative CRT regimen. The study data were prospectively collected using REDCap. The primary endpoint was the response by RECIST v.1.1 at 24 weeks(w). The secondary endpoints included toxicity by CTCAE v.5.0, PFS, and OS. Results We enrolled 40 consecutive pts between Aug/2019-Dec/2022 in a tertiary cancer center in Brazil. The median age was 61.6y, the majority were stage III (n = 31, 77.5%) and ECOG 1 (n = 20, 50%). HIV + serology was observed in 11 pts (27,5%). All patients received CRT, with a median dose of 54Gy in the primary tumor and 45Gy in the elective nodes. At 8w, 35% (n = 14) had a complete response (CR), 50% (n = 20) partial response (PR), and 2.5% (n = 1) progressive disease (PD). Considering the 35 participants evaluable for response at 24 weeks months by RECIST v.1.1, the disease control rate was 88.5% (n = 31). CR was observed in 47,5% (n = 19), PR in 20% (n = 8), and PD in 12,5% (n = 5). 11 pts had disease recurrence, and six died. The 1y estimated OS was 94.7% (IC95%: 80.7–98.6%), and 1y estimated PFS was 75.3% (IC95%:57.8–86.3%). Colostomy-free survival at one year was 89.6% (IC95%: 74.7–95.9%). Regarding toxicities, any grade 3/4 toxicity was present in 45% (n = 18) being the main G3/4 clinical toxicity radiodermatitis. Conclusions The CRT regimen with C + CDDP represents an alternative treatment for localized anal canal tumors in a population that does not have access to MMC and 5-FU infusion pumps. Further studies in this population are encouraged to confirm these findings.

BMC Cancer
Instituto do Câncer do Estado de São Paulo (BR)
Good health and well-being
Colorectal and Anal Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon